These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31714773)

  • 1. Promiscuity of in Vitro Secondary Pharmacology Assays and Implications for Lead Optimization Strategies.
    Brown DG; Smith GF; Wobst HJ
    J Med Chem; 2020 Jun; 63(12):6251-6275. PubMed ID: 31714773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of virtual and high throughput screening in lead discovery settings.
    Polgár T; Keseru GM
    Comb Chem High Throughput Screen; 2011 Dec; 14(10):889-97. PubMed ID: 21843143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling promiscuity based on in vitro safety pharmacology profiling data.
    Azzaoui K; Hamon J; Faller B; Whitebread S; Jacoby E; Bender A; Jenkins JL; Urban L
    ChemMedChem; 2007 Jun; 2(6):874-80. PubMed ID: 17492703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
    Sanders JM; Beshore DC; Culberson JC; Fells JI; Imbriglio JE; Gunaydin H; Haidle AM; Labroli M; Mattioni BE; Sciammetta N; Shipe WD; Sheridan RP; Suen LM; Verras A; Walji A; Joshi EM; Bueters T
    J Med Chem; 2017 Aug; 60(16):6771-6780. PubMed ID: 28418656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Can we discover pharmacological promiscuity early in the drug discovery process?
    Peters JU; Hert J; Bissantz C; Hillebrecht A; Gerebtzoff G; Bendels S; Tillier F; Migeon J; Fischer H; Guba W; Kansy M
    Drug Discov Today; 2012 Apr; 17(7-8):325-35. PubMed ID: 22269136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity-aware clustering of high throughput screening data and elucidation of orthogonal structure-activity relationships.
    Lounkine E; Nigsch F; Jenkins JL; Glick M
    J Chem Inf Model; 2011 Dec; 51(12):3158-68. PubMed ID: 22098146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-stoichiometric inhibition in integrated lead finding - a literature review.
    Klumpp M
    Expert Opin Drug Discov; 2016; 11(2):149-62. PubMed ID: 26653534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodiversity of small molecules--a new perspective in screening set selection.
    Petrone PM; Wassermann AM; Lounkine E; Kutchukian P; Simms B; Jenkins J; Selzer P; Glick M
    Drug Discov Today; 2013 Jul; 18(13-14):674-80. PubMed ID: 23454345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biophysics: for HTS hit validation, chemical lead optimization, and beyond.
    Genick CC; Wright SK
    Expert Opin Drug Discov; 2017 Sep; 12(9):897-907. PubMed ID: 28658992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series.
    Duffy BC; Zhu L; Decornez H; Kitchen DB
    Bioorg Med Chem; 2012 Sep; 20(18):5324-42. PubMed ID: 22938785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing Molecular Promiscuity Evaluation Through Assay Profiles.
    Avram S; Curpan R; Bora A; Neanu C; Halip L
    Pharm Res; 2018 Oct; 35(11):240. PubMed ID: 30338400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug promiscuity].
    Guo ZR
    Yao Xue Xue Bao; 2011 Apr; 46(4):361-9. PubMed ID: 21751487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety screening in early drug discovery: An optimized assay panel.
    Bendels S; Bissantz C; Fasching B; Gerebtzoff G; Guba W; Kansy M; Migeon J; Mohr S; Peters JU; Tillier F; Wyler R; Lerner C; Kramer C; Richter H; Roberts S
    J Pharmacol Toxicol Methods; 2019; 99():106609. PubMed ID: 31284073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High throughput technologies in drug discovery.
    Kundu B
    Comb Chem High Throughput Screen; 2011 Dec; 14(10):829. PubMed ID: 21843140
    [No Abstract]   [Full Text] [Related]  

  • 15. Combinatorial Pharmacophore-Based 3D-QSAR Analysis and Virtual Screening of FGFR1 Inhibitors.
    Zhou N; Xu Y; Liu X; Wang Y; Peng J; Luo X; Zheng M; Chen K; Jiang H
    Int J Mol Sci; 2015 Jun; 16(6):13407-26. PubMed ID: 26110383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological promiscuity: dependence on compound properties and target specificity in a set of recent Roche compounds.
    Peters JU; Schnider P; Mattei P; Kansy M
    ChemMedChem; 2009 Apr; 4(4):680-6. PubMed ID: 19266525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of triaging in determining the quality of output from high-throughput screening.
    Jones P; McElroy S; Morrison A; Pannifer A
    Future Med Chem; 2015; 7(14):1847-52. PubMed ID: 26419190
    [No Abstract]   [Full Text] [Related]  

  • 18. Approaches for high-throughput pharmacokinetic screening of low-molecular-weight drug candidates.
    Fontana S
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):139-42. PubMed ID: 24329157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modern drug discovery technologies: opportunities and challenges in lead discovery.
    Guido RV; Oliva G; Andricopulo AD
    Comb Chem High Throughput Screen; 2011 Dec; 14(10):830-9. PubMed ID: 21843147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening.
    Zuegg J; Cooper MA
    Curr Top Med Chem; 2012; 12(14):1500-13. PubMed ID: 22827520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.